Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05896670 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease
A Phase 2 study, sponsored by Oculis.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
NCT05896670 is a Phase 2 study that has completed, run by Oculis. The registered enrollment target is 122 participants.
The verdict
NCT05896670, a Phase 2 study, has completed, sponsored by Oculis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn about licaminlimab (OCS-02) in the treatment of dry eye disease. The main question it aims to answer is if licaminlimab ophthalmic solution is more effective than vehicle in treating signs of dry eye disease.
Interventions
- DRUG licaminlimab
- OTHER vehicle of OCS-02
- OTHER Artificial tears
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2023-11-29 |
| Est. Completion | 2024-03-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05896670
The ClinicalTrials.gov registry entry for NCT05896670 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oculis, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which licaminlimab is the first listed.
NCT05896670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05896670 about?
NCT05896670 is a clinical study titled "Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease". The goal of this clinical trial is to learn about licaminlimab (OCS-02) in the treatment of dry eye disease. The main question it aims to answer is if licaminlimab ophthalmic solution is more effective than vehicle in treating signs of dry eye disease.
What is the current status of trial NCT05896670?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2023-11-29. Estimated completion is 2024-03-27.
What interventions are being tested in trial NCT05896670?
The interventions under investigation include: licaminlimab (DRUG), vehicle of OCS-02 (OTHER), Artificial tears (OTHER).
Who is sponsoring clinical trial NCT05896670?
This trial is sponsored by Oculis, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.